摘要
目的探讨脓毒症心肌病患者接受参附注射液联合左西孟旦治疗的临床效果。方法从廉江市人民医院重症医学科患者中选择脓毒症心肌病患者60例(2022年1月-2023年9月)为对象,根据随机数字表法将60例患者分为两组,每组各30例,均接受基础治疗和器官功能支持治疗,在此基础上,给予对照组左西孟旦治疗,给予观察组参附注射液联合左西孟旦治疗。对比治疗前及治疗7d后的超声心动左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、肌钙蛋白Ⅰ(cTnⅠ)、氨基末端脑利钠肽前体(NT-proBNP)、血清白介素6(IL-6)、超敏C反应蛋白(hs-CRP)、内皮素1(ET-1)水平变化,统计两组不良反应。结果观察组治疗后LVEDD短于对照组,LVEF高于对照组(P<0.05);观察组治疗后cTnⅠ、NT-proBNP、IL-6、hs-CRP、ET-1水平低于对照组(P<0.05);两组不良反应发生率基本一致(P>0.05)。结论脓毒症心肌病患者接受参附注射液联合左西孟旦治疗,可改善其心功能,减轻炎症反应,调节cTnⅠ、NT-proBNP水平,且不会额外增加不良反应。
Objective To explore and analyze the clinical efficacy of Shenfu Injection combined with Levosimendan in the treatment of sepsis cardiomyopathy patients.Method Sixty patients with sepsis cardiomyopathy(from January 2022 to September 2023)were selected from the Intensive Care Department of Lianjiang People’s Hospital as the subjects.According to the random number table method,the 60 patients were divided into two groups,each with 30 cases,receiving basic treatment and organ function support treatment.On this basis,the control group was treated with Levosimendan,while the observation group was treated with Shenfu Injection combined with Levosimendan.Compare the changes in left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD),cardiac troponin I(cTnI),N-terminal pro brain natriuretic peptide(NT-proBNP),serum interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),and endothelin-1(ET-1)levels before and 7 days after treatment,and calculate the adverse reactions between the two groups.Result After treatment,the LVEDD of the observation group was shorter than that of the control group,and the LVEF was higher than that of the control group(P<0.05);after treatment,the levels of cTnⅠ,NT-proBNP,IL-6,hs-CRP,and ET-1 in the observation group were lower than those in the control group(P<0.05);the incidence of adverse reactions in the two groups was basically consistent(P>0.05).Conclusion Patients with sepsis cardiomyopathy treated with Shenfu Injection combined with Levosimendan can improve their cardiac function,alleviate inflammatory reactions,regulate cTnⅠand NT proBNP levels,and do not increase additional adverse reactions.
作者
杨根
刘华春
郭辉
胡巧
Yang Gen;Liu Huachun;Guo Hui;Hu Qiao(Department of Critical Care Medicine,Lianjiang People’s Hospital,Zhanjiang,Guangdong 524400,China)
出处
《首都食品与医药》
2024年第14期170-172,共3页
Capital Food Medicine
基金
湛江市科技计划项目(项目编号:211011114544398)。
